Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Adjuvant Therapy After Resection for High-Risk Hepatocellular Carcinoma
ChiCTR2600123910Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Recurrence-Free Survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600123910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123910.